,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,totalDebt,quickRatio,currentRatio,returnOnAssets,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,631 US Hwy 1,Suite 407,North Palm Beach,FL,33408,United States,612 961 5656,https://www.nascentbiotech.com,Biotechnology,Healthcare,"Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.","{'maxAge': 1, 'name': 'Mr. Sean  Carrick', 'age': 54, 'title': 'Pres, CEO, Sec. & Director', 'yearBorn': 1968, 'fiscalYear': 2023, 'totalPay': 252000, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.115,0.115,0.10555,0.115,0.115,0.115,0.10555,0.115,0.0,-2.851659,202565,202565,165208,283787,283787,0.0,0.0,0,0,16908980,0.0323,0.4515,0.0692574,0.08801705,0.0,0.0,USD,17176448,0.0,89285274,149636992,0.41641998,0.00746,-0.008,1680220800,1711843200,1688083200,-2041317,-0.02,PNK,EQUITY,NBIO,NBIO,NASCENT BIOTECH INC,"Nascent Biotech, Inc.",1259850600,America/New_York,EDT,-14400000,0.113,none,9480,0.0,276972,0.008,0.064,-9.76207,-1015985,-1606095,0.0,0.0,0.0,USD,
1,631 US Hwy 1,Suite 407,North Palm Beach,FL,33408,United States,612 961 5656,https://www.nascentbiotech.com,Biotechnology,Healthcare,"Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.","{'maxAge': 1, 'name': 'Mr. Lowell  Holden', 'age': 79, 'title': 'CFO, Chief Accounting Officer & Director', 'yearBorn': 1943, 'fiscalYear': 2023, 'totalPay': 180000, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.115,0.115,0.10555,0.115,0.115,0.115,0.10555,0.115,0.0,-2.851659,202565,202565,165208,283787,283787,0.0,0.0,0,0,16908980,0.0323,0.4515,0.0692574,0.08801705,0.0,0.0,USD,17176448,0.0,89285274,149636992,0.41641998,0.00746,-0.008,1680220800,1711843200,1688083200,-2041317,-0.02,PNK,EQUITY,NBIO,NBIO,NASCENT BIOTECH INC,"Nascent Biotech, Inc.",1259850600,America/New_York,EDT,-14400000,0.113,none,9480,0.0,276972,0.008,0.064,-9.76207,-1015985,-1606095,0.0,0.0,0.0,USD,
2,631 US Hwy 1,Suite 407,North Palm Beach,FL,33408,United States,612 961 5656,https://www.nascentbiotech.com,Biotechnology,Healthcare,"Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.","{'maxAge': 1, 'name': 'Dr. Mark C. Glassy Ph.D.', 'age': 70, 'title': 'Founder', 'yearBorn': 1952, 'fiscalYear': 2015, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.115,0.115,0.10555,0.115,0.115,0.115,0.10555,0.115,0.0,-2.851659,202565,202565,165208,283787,283787,0.0,0.0,0,0,16908980,0.0323,0.4515,0.0692574,0.08801705,0.0,0.0,USD,17176448,0.0,89285274,149636992,0.41641998,0.00746,-0.008,1680220800,1711843200,1688083200,-2041317,-0.02,PNK,EQUITY,NBIO,NBIO,NASCENT BIOTECH INC,"Nascent Biotech, Inc.",1259850600,America/New_York,EDT,-14400000,0.113,none,9480,0.0,276972,0.008,0.064,-9.76207,-1015985,-1606095,0.0,0.0,0.0,USD,
3,631 US Hwy 1,Suite 407,North Palm Beach,FL,33408,United States,612 961 5656,https://www.nascentbiotech.com,Biotechnology,Healthcare,"Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.","{'maxAge': 1, 'name': 'Dr. Navpaul  Singh M.D.', 'title': 'Chief Medical Consultant', 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.115,0.115,0.10555,0.115,0.115,0.115,0.10555,0.115,0.0,-2.851659,202565,202565,165208,283787,283787,0.0,0.0,0,0,16908980,0.0323,0.4515,0.0692574,0.08801705,0.0,0.0,USD,17176448,0.0,89285274,149636992,0.41641998,0.00746,-0.008,1680220800,1711843200,1688083200,-2041317,-0.02,PNK,EQUITY,NBIO,NBIO,NASCENT BIOTECH INC,"Nascent Biotech, Inc.",1259850600,America/New_York,EDT,-14400000,0.113,none,9480,0.0,276972,0.008,0.064,-9.76207,-1015985,-1606095,0.0,0.0,0.0,USD,
